AIMS/HYPOTHESIS: Circulating lipopolysaccharide-binding protein (LBP) is an acute-phase reactant known to be increased in obesity. We hypothesised that LBP is produced by adipose tissue (AT) in association with obesity. METHODS: LBP mRNA and LBP protein levels were analysed in AT from three cross-sectional (n = 210, n = 144 and n = 28) and three longitudinal (n = 8, n = 25, n = 20) human cohorts; in AT from genetically manipulated mice; in isolated adipocytes; and in human and murine cell lines. The effects of a high-fat diet and exposure to lipopolysaccharide (LPS) and peroxisome proliferator-activated receptor (PPAR)γ agonist were explored. Functional in vitro and ex vivo experiments were also performed. RESULTS: LBP synthesis and release was demonstrated to increase with adipocyte differentiation in human and mouse AT, isolated adipocytes and human and mouse cell lines (Simpson-Golabi-Behmel syndrome [SGBS], human multipotent adipose-derived stem [hMAD] and 3T3-L1 cells). AT LBP expression was robustly associated with inflammatory markers and increased with metabolic deterioration and insulin resistance in two independent cross-sectional human cohorts. AT LBP also increased longitudinally with weight gain and excessive fat accretion in both humans and mice, and decreased with weight loss (in two other independent cohorts), in humans with acquired lipodystrophy, and after ex vivo exposure to PPARγ agonist. Inflammatory agents such as LPS and TNF-α led to increased AT LBP expression in vivo in mice and in vitro, while this effect was prevented in Cd14-knockout mice. Functionally, LBP knockdown using short hairpin (sh)RNA or anti-LBP antibody led to increases in markers of adipogenesis and decreased adipocyte inflammation in human adipocytes. CONCLUSIONS/ INTERPRETATION: Collectively, these findings suggest that LBP might have an essential role in inflammation- and obesity-associated AT dysfunction.
AIMS/HYPOTHESIS: Circulating lipopolysaccharide-binding protein (LBP) is an acute-phase reactant known to be increased in obesity. We hypothesised that LBP is produced by adipose tissue (AT) in association with obesity. METHODS: LBP mRNA and LBP protein levels were analysed in AT from three cross-sectional (n = 210, n = 144 and n = 28) and three longitudinal (n = 8, n = 25, n = 20) human cohorts; in AT from genetically manipulated mice; in isolated adipocytes; and in human and murine cell lines. The effects of a high-fat diet and exposure to lipopolysaccharide (LPS) and peroxisome proliferator-activated receptor (PPAR)γ agonist were explored. Functional in vitro and ex vivo experiments were also performed. RESULTS: LBP synthesis and release was demonstrated to increase with adipocyte differentiation in human and mouse AT, isolated adipocytes and human and mouse cell lines (Simpson-Golabi-Behmel syndrome [SGBS], human multipotent adipose-derived stem [hMAD] and 3T3-L1 cells). AT LBP expression was robustly associated with inflammatory markers and increased with metabolic deterioration and insulin resistance in two independent cross-sectional human cohorts. AT LBP also increased longitudinally with weight gain and excessive fat accretion in both humans and mice, and decreased with weight loss (in two other independent cohorts), in humans with acquired lipodystrophy, and after ex vivo exposure to PPARγ agonist. Inflammatory agents such as LPS and TNF-α led to increased AT LBP expression in vivo in mice and in vitro, while this effect was prevented in Cd14-knockout mice. Functionally, LBP knockdown using short hairpin (sh)RNA or anti-LBP antibody led to increases in markers of adipogenesis and decreased adipocyte inflammation in human adipocytes. CONCLUSIONS/ INTERPRETATION: Collectively, these findings suggest that LBP might have an essential role in inflammation- and obesity-associated AT dysfunction.
Authors: J M Moreno-Navarrete; F Ortega; M Serino; E Luche; A Waget; G Pardo; J Salvador; W Ricart; G Frühbeck; R Burcelin; J M Fernández-Real Journal: Int J Obes (Lond) Date: 2011-12-20 Impact factor: 5.095
Authors: M Osto; E Zini; M Franchini; C Wolfrum; F Guscetti; M Hafner; M Ackermann; C E Reusch; T A Lutz Journal: Endocrinology Date: 2011-01-25 Impact factor: 4.736
Authors: Marta Giralt; Pere Domingo; Jordi P Guallar; M Luísa Rodriguez de la Concepción; Marta Alegre; Joan C Domingo; Francesc Villarroya Journal: Antivir Ther Date: 2006
Authors: Matt J Neville; Jenny M Collins; Anna L Gloyn; Mark I McCarthy; Fredrik Karpe Journal: Obesity (Silver Spring) Date: 2010-10-14 Impact factor: 5.002
Authors: Elham M Youssef-Elabd; Kirsty C McGee; Gyanendra Tripathi; Nasser Aldaghri; Mohga S Abdalla; Hayat M Sharada; Esmat Ashour; Ashraf I Amin; Antonio Ceriello; Joseph P O'Hare; Sudhesh Kumar; Philip G McTernan; Alison L Harte Journal: J Nutr Biochem Date: 2011-03-16 Impact factor: 6.048
Authors: Luca Miele; Giovanni Gasbarrini; Valentina Giorgio; Antonio Gasbarrini; Antonio Grieco Journal: Intern Emerg Med Date: 2015-11-24 Impact factor: 3.397
Authors: Faith I Umoh; Ikuko Kato; Jianwei Ren; Phillip L Wachowiak; Mack T Ruffin; D Kim Turgeon; Ananda Sen; Dean E Brenner; Zora Djuric Journal: Eur J Nutr Date: 2015-04-24 Impact factor: 5.614
Authors: Curtis M Tilves; Joseph M Zmuda; Allison L Kuipers; Cara S Nestlerode; Rhobert W Evans; Clareann H Bunker; Alan L Patrick; Iva Miljkovic Journal: Diabetes Care Date: 2015-12-30 Impact factor: 19.112
Authors: Aleix Gavaldà-Navarro; José M Moreno-Navarrete; Tania Quesada-López; Montserrat Cairó; Marta Giralt; José M Fernández-Real; Francesc Villarroya Journal: Diabetologia Date: 2016-06-25 Impact factor: 10.122